Trade Theravance Biopharma, Inc. - TBPH CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.11 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023401% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001179% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 9.78 |
| Open | 9.7 |
| 1-Year Change | -11.82% |
| Day's Range | 9.7 - 9.85 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 24, 2024 | 9.80 | 0.14 | 1.45% | 9.66 | 9.86 | 9.66 |
| Dec 23, 2024 | 9.78 | 0.26 | 2.73% | 9.52 | 9.96 | 9.45 |
| Dec 20, 2024 | 9.58 | 0.15 | 1.59% | 9.43 | 9.79 | 9.39 |
| Dec 19, 2024 | 9.71 | 0.21 | 2.21% | 9.50 | 9.81 | 9.42 |
| Dec 18, 2024 | 9.70 | -0.13 | -1.32% | 9.83 | 10.05 | 9.59 |
| Dec 17, 2024 | 9.89 | 0.41 | 4.32% | 9.48 | 9.94 | 9.45 |
| Dec 16, 2024 | 9.76 | 0.25 | 2.63% | 9.51 | 10.02 | 9.51 |
| Dec 13, 2024 | 9.82 | 0.04 | 0.41% | 9.78 | 9.88 | 9.69 |
| Dec 12, 2024 | 9.85 | 0.28 | 2.93% | 9.57 | 10.02 | 9.57 |
| Dec 11, 2024 | 9.98 | 0.08 | 0.81% | 9.90 | 10.05 | 9.84 |
| Dec 10, 2024 | 10.01 | 0.16 | 1.62% | 9.85 | 10.10 | 9.77 |
| Dec 9, 2024 | 9.95 | 0.29 | 3.00% | 9.66 | 10.22 | 9.63 |
| Dec 6, 2024 | 9.85 | 0.34 | 3.58% | 9.51 | 9.97 | 9.51 |
| Dec 5, 2024 | 9.79 | 0.46 | 4.93% | 9.33 | 9.84 | 9.22 |
| Dec 4, 2024 | 9.52 | -0.24 | -2.46% | 9.76 | 9.92 | 9.49 |
| Dec 3, 2024 | 9.76 | 0.36 | 3.83% | 9.40 | 9.80 | 9.32 |
| Dec 2, 2024 | 9.22 | 0.14 | 1.54% | 9.08 | 9.49 | 9.03 |
| Nov 29, 2024 | 9.22 | -0.22 | -2.33% | 9.44 | 9.46 | 9.14 |
| Nov 27, 2024 | 9.38 | 0.16 | 1.74% | 9.22 | 9.41 | 9.19 |
| Nov 26, 2024 | 9.22 | -0.11 | -1.18% | 9.33 | 9.36 | 8.96 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Theravance Biopharma, Inc. Company profile
About Theravance Biopharma Inc
Theravance Biopharma, Inc. is a diversified biopharmaceutical company, which is primarily focused on the discovery, development and commercialization of organ-selective medicines. The Company develops transformational medicines to improve the lives of patients suffering from serious illnesses. The Company's research is focused in the areas of inflammation and immunology. It applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The Company is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Theravance Biopharma Inc revenues decreased 23% to $55.3M. Net loss decreased 28% to $199.4M. Revenues reflect U.S. segment decrease of 21% to $55.3M, Europe segment decrease of 98% to $38K. Lower net loss reflects Research and development - bal decrease of 27% to $166.6M (expense), Selling, general and administrative -bal decrease of 55% to $31M (expense).
| Industry: | Pharmaceuticals (NEC) |
Ugland House, South Church Street
GEORGE TOWN
GRAND CAYMAN KY1-1104
KY
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com